TherapyX

TherapyX is pioneering a novel drug delivery platform, EXStaM, designed to encapsulate and deliver large biologic molecules orally and via other routes while preserving their full biological activity. Its pipeline includes several preclinical and early-stage programs targeting pancreatic cancer, gonorrhea, and Familial Adenomatous Polyposis (FAP), with one program having received FDA Orphan Drug Designation. Founded in 2016 by academic scientists, the company is privately held, pre-revenue, and has secured non-dilutive funding from grants, including a recent $3 million NIH award.

EXStaM: A patented process for producing sustained-release microparticulate protein therapeutics that maintain full biological activity, enabling oral, mucosal, and parenteral delivery directly to the disease microenvironment.

TherapyX competes in the crowded and technically challenging field of oral biologic delivery, facing companies with alternative encapsulation, permeation enhancer, and formulation technologies. Its success depends on demonstrating superior bioavailability, stability, and targeted delivery compared to these alternatives and to the standard of injectable biologics.